Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response

Oncogene

Volumn 29, Issue 32, 2010, Pages 4517-4527

  Hartmann, C ^a   Muller N ^a   Blaukat, A ^b   Koch, J ^a   Benhar, I ^c   Wels, W S ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^b Merck Serono GmbH   (Germany)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

epidermal growth factor receptor; peptide mimotope; phage display; therapeutic antibody

Indexed keywords

ALANYLCYSTEINYLLYSYLTYROSYLPROLYLLEUCYLGLYCYLHISTIDYLGLUTAMINYLCYSTEINYLGLYCYLGLYCYLGLYCYLSERINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; MATUZUMAB; PEPTIDE ANTIBODY; PEPTIDE LIBRARY; PEPTIDE MIMOTOPE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VALYLLEUCYLPROLYLLYSYLTHREONYLLEUCYLCYSTEINYLGLYCYLGLYCYLGLYCYLSERINE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CROSS REACTION; EPITOPE MAPPING; EXPERIMENTAL RABBIT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN MOTIF;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; CROSS REACTIONS; EPITOPES; HUMANS; IMMUNOTHERAPY; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEOPLASMS; PEPTIDE LIBRARY; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

ANIMALIA;

EID: 77955655880     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.195     Document Type: Article

References (34)

1. Azemar M, Schmidt M, Arlt F, Kennel P, Brandt B, Papadimitriou A et al. (2000). Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int J Cancer 86: 269-275.
2. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R et al. (2005). Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23: 5568-5577.
3. Benhar I, Azriel R, Nahary L, Shaky S, Berdichevsky Y, Tamarkin A et al. (2000). Highly efficient selection of phage antibodies mediated by display of antigen as Lpp-OmpA' fusions on live bacteria. J Mol Biol 301: 893-904.
4. Brandt O, Dietrich U, Koch J. (2009). Solid-supported peptide arrays in the investigation of protein-protein and protein-nucleic acid interactions. Curr Chem Biol 3: 171-179.
5. Cochran JR, Kim YS, Olsen MJ, Bhandari R, Wittrup KD. (2004). Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. J Immunol Methods 287: 147-158.
6. Georgiou G, Stathopoulos C, Daugherty PS, Nayak AR, Iverson BL, Curtiss III R. (1997). Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines. Nat Biotechnol 15: 29-34.
7. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. (1995). Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1: 1311-1318.
8. Groner B, Hartmann C, Wels W. (2004). Therapeutic antibodies. Curr Mol Med 4: 539-547.
9. Humphrey W, Dalke A, Schulten K. (1996). VMD: Visual Molecular Dynamics. J Mol Graph 14: 33-38, 27-38.
10. Hynes NE, Lane HA. (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354.
11. Hynes NE, MacDonald G. (2009). ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21: 177-184.
12. Kettleborough CA, Saldanha J, Heath VJ, Morrison CJ, Bendig MM. (1991). Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng 4: 773-783.
13. Leahy DJ. (2008). A molecular view of anti-ErbB monoclonal antibody therapy. Cancer Cell 13: 291-293.
14. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. (2005). Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7: 301-311.
15. Maurer-Gebhard M, Schmidt M, Azemar M, Altenschmidt U, Stocklin E, Wels W et al. (1998). Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells. Cancer Res 58: 2661-2666.
16. Mayrose I, Penn O, Erez E, Rubinstein ND, Shlomi T, Freund NT et al. (2007a). Pepitope: epitope mapping from affinity-selected peptides. Bioinformatics 23: 3244-3246.
17. Mayrose I, Shlomi T, Rubinstein ND, Gershoni JM, Ruppin E, Sharan R et al. (2007b). Epitope mapping using combinatorial phage-display libraries: a graph-based algorithm. Nucleic Acids Res 35: 69-78.
18. Mendelsohn J, Baselga J. (2006). Epidermal growth factor receptor targeting in cancer. Semin Oncol 33: 369-385.
19. Murthy U, Basu A, Rodeck U, Herlyn M, Ross AH, Das M. (1987). Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys 252: 549-560.
20. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH et al. (2002). Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110: 775-787.
21. Partidos CD. (2000). Peptide mimotopes as candidate vaccines. Curr Opin Mol Ther 2: 74-79.
22. Rao S, Starling N, Cunningham D, Benson M, Wotherspoon A, Lupfert C et al. (2008). Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer 99: 868-874.
23. Riemer AB, Klinger M, Wagner S, Bernhaus A, Mazzucchelli L, Pehamberger H et al. (2004). Generation of peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J Immunol 173: 394-401.
24. Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E. (2005). Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst 97: 1663-1670.
25. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. (1983). Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1: 511-529.
26. Schmidt M, Maurer-Gebhard M, Groner B, Kohler G, Brochmann-Santos G, Wels W. (1999). Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors. Oncogene 18: 1711-1721.
27. Schmidt M, Wels W. (1996). Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha. Br J Cancer 74: 853-862.
28. Schmiedel J, Blaukat A, Li S, Knochel T, Ferguson KM. (2008). Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell 13: 365-373.
29. Seiden MV, Burris HA, Matulonis U, Hall JB, Armstrong DK, Speyer J et al. (2007). A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol 104: 727-731.
30. Shomura H, Shichijo S, Matsueda S, Kawakami T, Sato Y, Todo S et al. (2004). Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2(+) cancer patients. Br J Cancer 90: 1563-1571.
31. Waterfield MD, Mayes EL, Stroobant P, Bennet PL, Young S, Goodfellow PN et al. (1982). A monoclonal antibody to the human epidermal growth factor receptor. J Cell Biochem 20: 149-161.
32. Wels W, Beerli R, Hellmann P, Schmidt M, Marte BM, Kornilova ES et al. (1995). EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int J Cancer 60: 137-144.
33. Wels W, Harwerth IM, Mueller M, Groner B, Hynes NE. (1992). Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res 52: 6310-6317.
34. Yarden Y, Sliwkowski MX. (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.